User:Mr. Ibrahem/Tenapanor

Mr. Ibrahem/Tenapanor

Clinical data
Trade names	Ibsrela
Other names	Tenapanor hydrochloride
AHFS/Drugs.com	Monograph
License data	US DailyMed: Tenapanor
Routes of administration	By mouth
Drug class	NHE3 inhibitors
Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name N,N'-(10,17,-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl)bis([(4S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl]benzenesulfonamide)
Chemical and physical data
Formula	C50H66Cl4N8O10S2
Molar mass	1145.04 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN1C[C@H](C2=C(C1)C(=CC(=C2)Cl)Cl)C3=CC(=CC=C3)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C4=CC=CC(=C4)[C@@H]5CN(CC6=C5C=C(C=C6Cl)Cl)C
InChI InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60H,3-4,11-24,31-34H2,1-2H3,(H2,55,57,63)(H2,56,58,64)/t43-,44-/m0/s1 Key:DNHPDWGIXIMXSA-CXNSMIOJSA-N

Tenapanor, sold under the brand name Ibsrela, is a medication used to treat irritable bowel syndrome with constipation (IBS-C). It is taken by mouth.

Common side effects include diarrhea, abdominal swelling, and lightheadedness. Use in pregnancy and breastfeeding is believed to be safe. It acts by blocking the sodium-proton exchanger NHE3 there by decreasing the uptake of sodium by the intestines.

Tenapanor was approved for medical use in the United States in 2019. As of 2021; however, it is not yet in pharmacies. As of 2021 it is not approved in Europe or the United Kingdom.